Türkiye’s Deva invests in oncology plant


Bugun - Deva, one of the leading pharmaceutical companies in Türkiye, is planning to establish an oncology plant, which will focus on cancer treatment. The plant, to be built in Cerkezkoy, Tekirdag, is expected to cost TRY 60 million and will specialize in cancer drugs. Deva CEO Phillipp Haas said they are planning to address the domestic and international need for medicines. “We have medicines under development for cardiovascular diseases, as well as antibiotics”, said Haas. The oncology plant in Cerkezkoy is slated to start production in three years.

Türkiye; pharmaceutical industry; pharmaceutical investment; healthcare; oncology research; cancer drugs; Deva Holding